Century Therapeutics, Inc. (IPSC)
| Market Cap | 1.35B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 12.04M |
| EPS (ttm) | -8.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,672,264 |
| Open | 29.01 |
| Previous Close | 29.25 |
| Day's Range | 24.51 - 30.32 |
| 52-Week Range | 18.93 - 32.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 36.25 (+46.4%) |
| Est. Earnings Date | Nov 11, 2021 |
About IPSC
Century Therapeutics is an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. We have created a comprehensive allogeneic cell therapy platform that allows us to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, our ...
News
Century Therapeutics Announces Its Addition to the Russell 2000® Index
PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno...
Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates
Continued Company investment across our iPSC platforms, programs, and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 Recent IPO with net proceeds of approximately $221...
Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purcha...
PHILADELPHIA, June 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-...
Century Therapeutics Announces Pricing of Initial Public Offering
PHILADELPHIA, June 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today...
Century Therapeutics IPO Registration Document (S-1)
Century Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.